OpGen Inc (OPGN) USD0.01

Sell:$3.40Buy:$3.40$0.18 (5.57%)

Prices delayed by at least 15 minutes
Sell:$3.40
Buy:$3.40
Change:$0.18 (5.57%)
Prices delayed by at least 15 minutes
Sell:$3.40
Buy:$3.40
Change:$0.18 (5.57%)
Prices delayed by at least 15 minutes

Company Information

About this company

OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.

Key people

John Tan Honjian
Chairman of the Board, Chief Executive Officer
Mohd Azham Azudin
Chief Operating Officer
Rou Yee Tan
Company Secretary
Christian-Laurent Bonte
Independent Director
Kok Hoe Victor Chua
Independent Director
Zhao Qi Ken Lim
Independent Director
Yu Jie Ethan Low
Independent Director
Poh Yin Constance Wong
Independent Director
Click to see more

Key facts

  • EPIC
    OPGN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Healthcare Facilities
  • ISIN
    US68373L5057
  • Market cap
    $32.42m
  • Employees
    100
  • Shares in issue
    10.07m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.